AR039613A1 - Derivados de morfolina, antagonistas de ccr3. - Google Patents

Derivados de morfolina, antagonistas de ccr3.

Info

Publication number
AR039613A1
AR039613A1 ARP030101085A ARP030101085A AR039613A1 AR 039613 A1 AR039613 A1 AR 039613A1 AR P030101085 A ARP030101085 A AR P030101085A AR P030101085 A ARP030101085 A AR P030101085A AR 039613 A1 AR039613 A1 AR 039613A1
Authority
AR
Argentina
Prior art keywords
methyl
substituted
dichlorobenzyl
morpholin
alkyl
Prior art date
Application number
ARP030101085A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR039613A1 publication Critical patent/AR039613A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Ciertos compuestos de fórmula (1), en la que: R1 representa heterociclilo sustituido o no sustituido; Y representa -(CRnaRnb)n-; cada uno de Rna y Rnb es independientemente hidrógeno o alquilo C1-6; n es un número entero de 1 a 5; R2 representa arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido; cada uno de R3 y R4 representa independientemente hidrógeno o alquilo C1-6; y sales y solvatos de los mismos son antagonistas de CCR3 y, de esta forma, están indicados por su utilidad en terapia. Reivindicación 1: Compuestos de fórmula (1), en la que: R1 representa heterociclilo sustituido o no sustituido; Y representa -(CRnaRnb)n-; cada uno de Rna y Rnb es independientemente hidrógeno o alquilo C1-6; n es un número entero de 1 a 5; R2 representa arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido; cada uno de R3 y R4 representa independientemente hidrógeno o alquilo C1-6; y sales y solvatos de los mismos; con la condición de que se excluyan los siguientes compuestos; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-[2-(2-oxoimidazolidin-1-il)etil]urea; 4-({[({[4-(3,4-diclorobencil)morfolin-2-il]metil}amino)carbonil]amino}metil)piperidina-1-carboxilato de terc-butilo; N-{[1-(ciclopropilcarbonil)piperidin-4-il]metil}-N'-{[(2S)-4-(3,4-diclorobencil)morfolin-2-il]metil}urea; y N-{[(2S)-4-(3,4-diclorobencil) morfolin-2-il]metil}-N'-{[1-(metilsulfonil)piperidin-4-il]metil}urea.
ARP030101085A 2002-03-28 2003-03-27 Derivados de morfolina, antagonistas de ccr3. AR039613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207439.1A GB0207439D0 (en) 2002-03-28 2002-03-28 Novel compounds

Publications (1)

Publication Number Publication Date
AR039613A1 true AR039613A1 (es) 2005-03-02

Family

ID=9933990

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101085A AR039613A1 (es) 2002-03-28 2003-03-27 Derivados de morfolina, antagonistas de ccr3.

Country Status (7)

Country Link
EP (1) EP1487454A1 (es)
JP (1) JP2005527557A (es)
AR (1) AR039613A1 (es)
AU (1) AU2003226763A1 (es)
GB (1) GB0207439D0 (es)
TW (1) TW200403063A (es)
WO (1) WO2003082295A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1801108B9 (en) 2004-09-08 2013-11-20 Mitsubishi Tanabe Pharma Corporation Morpholine compounds for the treatment of inflammations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101398T2 (tr) * 1998-11-20 2001-09-21 F.Hoffmann-La Roche Ag Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
WO2002026723A1 (en) * 2000-09-29 2002-04-04 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
TW200403063A (en) 2004-03-01
GB0207439D0 (en) 2002-05-08
EP1487454A1 (en) 2004-12-22
AU2003226763A1 (en) 2003-10-13
JP2005527557A (ja) 2005-09-15
WO2003082295A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
RU2007148217A (ru) Получение производных n-фенил-2-пиримидинамина
NO20030471L (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
PE20081059A1 (es) Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk)
EA200600509A1 (ru) Соединения пиримидотиофена
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
MEP22008A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
ATE537169T1 (de) Piperidin- und piperazinderivate als p2x3- antagonisten
CO4950625A1 (es) Derivados de nicotinamida
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
ATE383338T1 (de) N-(phenyl(piperidin-2-yl)methyl)benzamid-deriva e,verfahren zu deren herstellung und ihre therapeutische verwendung
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
AR039172A1 (es) Derivados de morfolina, antagonistas de ccr3.
CO5631438A2 (es) Profarmacos de aminoacidos excitadores
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
NO20064175L (no) Heterosyklisk forbindelse
AR039613A1 (es) Derivados de morfolina, antagonistas de ccr3.
PE20090967A1 (es) Derivados de imidazolidina 2,4-diona como moduladores del receptor npy y2
CO5540311A2 (es) Derivados de pirimidina utiles como inhibidores de cox-2 selectivos
AR040782A1 (es) Derivados de 5- cicloalquenil-5h- cromeno [ 3,4- f] quinolina como compuestos mudulares selectivos de receptores de progesterona
AR039175A1 (es) Derivados de morfolina, antagonistas de ccr3
CO5590900A2 (es) Fenilalquinos
DK0630893T3 (da) N,N'-disubstitueret amidderivat
NO20064299L (no) Indanolderivat

Legal Events

Date Code Title Description
FB Suspension of granting procedure